Search This Blog

Wednesday, October 21, 2026

Roivant: positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib in non-infectious uveitis

targets sNDA filing in 1H 2027

https://finviz.com/stock?t=ROIV&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)